Human il 6 quantikine elisa

We were especially interested in IL-6 levels in our study cohort, as IL-6 targeting therapy satralizumab was already approved for AQP4+ NMOSD (15 (link), 16 (link)). Therefore, the concentration of IL-6 in the serum was quantified by ELISA from five different manufacturers (Thermo Fisher Scientific, Waltham, MA, USA; IL-6 Human high sensitivity ELISA, cat. #BMS213HS, henceforth referred to as ELISA 1; R&D Systems, Minneapolis, MN, USA; Human IL-6 Quantikine ELISA, cat. #D6050, henceforth referred to as ELISA 2; Mabtech, Cincinnati, OH, USA; Human IL-6 ELISA Pro, cat. #3460-1HP-2, henceforth referred to as ELISA 3; Abcam, Cambridge, CB, UK; Human IL-6 ELISA Kit, cat. #ab178013, henceforth referred to as ELISA 4; Biolegend, San Diego, CA, USA; MAX Human IL-6 ELISA, cat. #430501, henceforth referred to as ELISA 5) according to the manufacturer’s instructions. Results were compared to bead-based assay 1 and with other bead-based assays described below. In samples where cytokines, chemokines and related molecules were undetectable, the values of the lower standard concentrations were used for analyses.

Supernatants were collected after SAHA treatment and kept in -80° C until the test. IL-6 and IL-8 secreted levels were analysed using Human IL-6 Quantikine® Elisa (R&D Systems) and Human IL-8 Quantikine® Elisa (R&D Systems) following manufacturer’s instructions. IL-6 and IL-8 secreted levels were quantified relative to total protein content.